MedTrace Logo

Metabolic Effects of Antipsychotic Substitution in Children

NCT00910780 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2014-03-13

No results posted yet for this study

Summary

This project aims to identify whether therapeutic substitution of aripiprazole for risperidone or olanzapine, combined with standard nutrition intervention, will impact the metabolic changes associated with antipsychotic treatment in children and adolescents.

Conditions

Interventions

DRUG

Aripiprazole

via oral tablets, everyday

DRUG

Zyprexa

via oral tablets, taken once daily

DRUG

Risperdal

via oral tablets, taken once daily

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • John W Newcomer, MD · Washington University School of Medicine and Florida Atlantic University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2009-11-30
Completion
2009-11-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00910780 on ClinicalTrials.gov